drugset / Trial / NCT00062686
GW572016 For Treatment Of Refractory Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.
Timeline
- Start
- 2003-11
- Primary completion
- 2005-02
- Completion
- 2005-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | — | Oral |